Skin toxicity is the most commonly reported adverse event secondary to immune checkpoint inhibitors for cancer treatment. It can vary in severity from grade 1 (mild) to grade 4 (life-threatening) and can result in discontinuation of valuable immunotherapy. This study determines the incidence of grade 3 and 4 skin toxicity secondary to multiple regimens of immune checkpoint inhibitors for multiple solid tumour types at a single tertiary oncology institution and explores the cutaneous presentation of severe skin toxicity, real world management, rates of discontinuation of immune checkpoint inhibitors and survival outcomes amongst this population.

This real-life study evaluated the safety of guselkumab in 1,024 patients with moderate-to-severe psoriasis who also had chronic infections, cancer, or heart disease. No viral reactivation occurred in patients with infections, and guselkumab was found to be safe for patients with cancer or heart disease. The findings provide valuable insights for managing psoriasis treatment in patients with these comorbidities.

In this nationwide cohort study conducted in Taiwan, we evaluated 13,245 psoriatic patients with a maximum follow-up of 18.0 years. Our findings suggest that PUVA therapy was associated with an increased risk of nonmelanoma skin cancer but not melanoma in Asian psoriatic patients with Fitzpatrick skin phototypes II to V.

Few studies have evaluated the long-term sequelae of Stevens–Johnson syndrome and toxic epidermal necrolysis. In this retrospective cohort study, we found that these patients had a significantly elevated risk of major cardiovascular event, ischaemic heart disease, cerebrovascular disease and mortality compared with healthy controls.

This study analyzes melanoma mortality trends across 28 European countries from 1992 to 2021, revealing significant variations by age, gender, and geography. While patients over 75 have been responsible for the increase in mortality until 2015, younger patients have shown a decline since the 1990s. The findings highlight the need for ongoing monitoring, particularly in Central and Eastern Europe and among men in Northern Europe, where recent increases in mortality rates have been observed.

We present the case of a 62-year-old man diagnosed with ARVD at 42, who exhibited severe right ventricular involvement requiring an implantable cardioverter-defibrillator. Genetic analysis identified a homozygous JUP variant (c.468G>A), previously reported as pathogenic but never in the homozygous state, expanding the disease's phenotypic spectrum and highlighting the importance of genetic screening and long-term follow-up.

Sonidegib is an orally administered Hedgehog inhibitor, approved for use in adult patients with locally advanced basal cell carcinoma who are not candidates for curative surgery or radiation therapy. It is well known that longer sonidegib intake may be related to adverse events which may have a deep impact on patients’ quality of life. More data are required to further investigate possible strategies to adopt to increase patients’compliance to treatment, reducing the risk of adverse events and increasing treatment outcomes. The aim of our study was to investigate the effect on tolerability of using sonidegib beyond clinical complete response in locally advanced basal cell carcinoma patients who had previously achieved clinical Complete Remission with sonidegib.

The aim of this retrospective study is to assess the efficacy of brodalumab in a multicenter Italian cohort of psoriasis patients, who had not achieved Psoriasis Area Severity Index (PASI) 75 or had lost response to any of the other IL-17 blockers (Bimekizumab, Ixekizumab, Secukinumab).

A 52-year-old male patient presented with a progressively enlarging, asymptomatic white papule on his right leg. Histopathological examination revealed fascicles of collagen separated by dense, diffuse deposits of mucin intermixed with numerous fibrocytes, and a few spindle-shaped fibroblasts with some vacuolization.

Nail findings in Darier's disease can often be confused with other nail pathologies. This Speciality Certificate Examination question aims to clarify the common nail findings which may be present on exam in Darier's disease.